The JCA Anticipation Window: Why the Evidence Challenge Starts Long Before the 100-Day Clock

What is the Evidence Challenge for JCA?

The evidence challenge for JCA (Joint Clinical Assessment) is managing multiple population, intervention/exposure, comparator, outcome, and study design (PI(E)COS) requests and indirect comparisons within a strict 100-day submission timeframe. The EU Health Technology Assessment Regulation has applied since 12 January 2025. While most commentary focuses on the formal 100-day dossier window, that period represents only the final visible deadline. Essential preparations happen earlier, during the anticipation window, when development teams can shape evidence without a regulatory clock running.

This article explains why that early period matters. It sets out the official timeline and what the first published reports showed. It then offers a practical workflow for the months before the scope arrives. Throughout, it separates what the Commission has published from what

Why the 100-Day Clock Masks a Longer Timeline

The formal JCA timeline looks deceptively short. After the consolidated list of PI(E)COS is communicated, manufacturers have roughly 100 days to submit the clinical dossier (60 days in accelerated procedures). Endorsement of the final JCA report is expected no later than 30 days after marketing authorisation.

In practice, the evidence challenge for JCA starts much earlier. Trial design decisions, comparator selection, and subgroup analyses must anticipate European standards of care that vary widely across Member States. For example, early published assessments of treatments in extensive-stage small cell lung cancer already showed how a single regulatory indication can generate multiple decision problems and several PI(E)COS.

Organisations that treat the 100-day period as the starting point routinely face incomplete indirect comparisons, missing subpopulation data, and rushed systematic literature reviews. The anticipation window, by contrast, allows teams to map likely PI(E)COS, build living evidence repositories, and validate extraction pipelines well before the formal request arrives.

JCA – Who Does What

The Five Stages of the EU JCA Process

Roles clarify where developers can contribute to the JCA process. The JCA subgroup of the HTA Coordination Group oversees each assessment and appoints an assessor and a co-assessor from different EU Member States. The assessor, supported by the co-assessor, reviews the submitted evidence and prepares the draft assessment and summary reports. The JCA subgroup finalizes the assessment scope and reports, with input from patients, clinical experts, and other relevant experts.

Developers have defined opportunities to participate. They can request an assessment scope explanation meeting, respond to requests for additional information, and identify technical or factual inaccuracies in the draft reports. They can also flag information they consider commercially sensitive, with appropriate justification. The HTA Coordination Group must endorse the reports no later than 30 days following the European Commission’s decision granting marketing authorization. The assessment is discontinued if the relevant marketing authorization application is withdrawn or the regulatory procedure has a negative outcome.

The JCA report presents scientific findings on relative clinical effectiveness and safety. It does not determine overall clinical added value or make reimbursement recommendations. When conducting national HTA for a technology covered by JCA, Member States must give due consideration to the joint report and annex the developer’s dossier to their national HTA documentation. This means the evidence submitted for JCA also remains relevant to subsequent national assessments.

What the First JCA Reports Revealed

The First Report: Tovorafenib

The Commission published the first JCA report on 9 June 2026. It covered tovorafenib (Ojemda) in pediatric low-grade glioma. The coordination group endorsed it on 30 April 2026. The product had received conditional marketing authorization in April 2026, supported by an uncontrolled phase II study.

According to Avalere Health’s analysis, the scope contained eight PI(E)COS, yet the report presented data for only one. That report still ran past 150 pages. It included an unanchored matching-adjusted indirect comparison, with strong caveats about uncertainty. Avalere also observed that unmet need did not moderate the evaluation criteria.

Later Reports: Comparative Evidence Across All PI(E)COS

Later reports told a different story. A commentary from Becaris notes that the second and third reports covered lurbinectedin and tarlatamab. Both assessed extensive-stage small cell lung cancer, and both offered comparative analyses across all PI(E)COS. The first report had evidence for only one of eight.

The commentary stresses that the difference lay in comparative evidence, not in PI(E)COS counts. The pattern suggests that comparator planning during development shapes results. However, three reports form a small sample, so teams should avoid firm conclusions.

What Remains Unknown

Each open question widens the evidence challenge for JCA. Avalere notes that it is unclear how national bodies will interpret the uncertainty the reports describe. Furthermore, it is unclear whether national assessors will consider evidence that the JCA did not accept. Plans for re-assessment also did not appear in the first report. Market access solutions that connect EU evidence planning to national submissions will need to track these answers.

How PI(E)COS Turn into Evidence Work

Each PI(E)COS is a comparison request. Developers can answer it in three ways. A head-to-head trial gives direct evidence. An indirect treatment comparison, such as a network meta-analysis, links separate studies through a common comparator. An external control draws on non-trial data when no randomized comparison exists.

Three Evidence Routes for Addressing JCA PI(E)COS

Why PI(E)COS Numbers Multiply

Scoping simulations show the multiplication effect. A review of early JCA subgroup exercises on three products reported 7 to 13 PI(E)COS each. An ISPOR report on a nivolumab simulation described a consolidation to at least 10 PI(E)COS. About five could use head-to-head data, and five needed indirect comparisons. The presenter calculated up to 280 requested analyses under simplifying assumptions.

Disease type matters. A published review of PI(E)COS scoping notes that dynamic indications generate far more PI(E)COS than rare diseases. Comparators and sub-populations drive most of the difference. The review also advises that preparation should begin well before the dossier deadline.

Feasibility Comes First

Each route has a feasibility test. Populations must be similar enough, outcome definitions must align, and patient-level data must be accessible. Therefore, the evidence challenge for JCA is a feasibility problem before it is a statistics problem. Teams that test feasibility early know which PI(E)COS they can answer.

Benefits and Use Cases

Organisations that invest in the anticipation window gain three measurable advantages. First, they reduce the risk of incomplete submissions. Second, they free specialist time for higher-value interpretation rather than repetitive screening. Third, they create reusable evidence assets that support subsequent national HTAs and label expansions.

Use cases already emerging include oncology assets with multiple lines of therapy, ATMPs that require complex comparator landscapes, and products entering the JCA process after accelerated regulatory pathways. In each case, early living reviews and pre-validated extraction frameworks allow teams to respond within the 100-day window without sacrificing quality.

Best Practices, Risks, and Limitations

Best practice begins with cross-functional alignment between clinical development, HEOR, and market access at the protocol stage. Joint Scientific Consultations provide valuable early signals and should be used whenever feasible. Living reviews must follow explicit update frequencies and PRISMA-aligned methods so that HTA bodies can audit the process.

However, risks remain. Over-reliance on predicted PI(E)COS can still leave gaps when Member States introduce unexpected populations or comparators. AI screening tools require rigorous validation against human reference standards; accuracy claims below documented thresholds undermine credibility. Finally, the JCA report itself is only one input into national decision-making, so teams must still plan for local adaptations.

A Phased Anticipation Workflow

Phases one to three happen inside the anticipation window. Phases four and five happen under the clock. The earlier phases decide how much of the later work is routine.

Future Trends in Continuous Evidence Generation

The direction of travel is clear. Evidence generation is moving from discrete projects toward continuous processes supported by agentic AI workflows. Platforms that orchestrate literature monitoring, automated extraction, and expert adjudication will become standard infrastructure. AI Life Sciences tools already demonstrate how retrieval-augmented generation and structured pipelines can maintain both speed and auditability.

As the JCA scope expands, the competitive advantage will belong to organisations that treat the anticipation window as a core capability rather than an optional extra. Life science solution providers that combine domain expertise with transparent AI will play a central role in helping teams meet this new standard.

Conclusion

The evidence challenge for JCA is not confined to the 100-day dossier period. It begins with trial design, continues through continuous literature synthesis, and only culminates in the formal submission. Companies that recognise this longer horizon and invest in living evidence systems, early PI(E)COS mapping, and validated AI-supported workflows position themselves to deliver robust, timely packages.

Those that treat the formal clock as the starting point will find the window too short. The practical path forward is clear: start the evidence work early, keep it living, and maintain full traceability at every step. Explore how continuous evidence approaches and an AI-assisted literature review platform can support your next JCA preparation.

Author’s Note: This article was supported by AI-based research and writing, with Claude 5 assisting in the creation of text and images.